NEW YORK (TheStreet) -- Shares ofBrainstorm Cell Therapeutics (BCLI) soared 20.88% to $4.69 on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday. <\/p>\n
Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an \"autologous, adult stem cell therapy technology\" designed to treat ALS, also known as Lou Gehrig's Disease. <\/p>\n
The company will host a conference call on Monday to discuss the results. <\/p>\n
Exclusive Report: Jim Cramers Best Stocks for 2015 <\/p>\n
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. <\/p>\n
Access the tool that DOMINATES the Russell 2000 and the S&P 500. <\/p>\n
Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. <\/p>\n
<\/p>\n
See the article here: <\/p>\n
Brainstorm Cell Therapeutics (BCLI) Stock Rises Ahead of ALS Treatment Trial Data Release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK (TheStreet) -- Shares ofBrainstorm Cell Therapeutics (BCLI) soared 20.88% to $4.69 on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday. Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday Continue reading